CoChat

Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness

Molina-Crespo, Ángela, Cadete, Ana, Sarrio, David, Gámez-Chiachio, Manuel, Martinez, Lidia, Chao, Kinlin, Olivera, Ana, Gonella, Andrea, Díaz, Eva, Palacios, José, Dhal, Pradeep K., Besev, Magnus, Rodríguez-Serrano, Macarena, García Bermejo, María Laura, Triviño, Juan Carlos, Cano, Amparo, García-Fuentes, Marcos, Herzberg, Osnat, Torres, Dolores, Alonso, Maria José, Moreno-Bueno, Gema · 2019 · Clinical Cancer Research
Cited by 118

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: Gasdermin B (GSDMB) overexpression/amplification occurs in about 60% of HER2 breast cancers, where it promotes cell migration, resistance to anti-HER2 therapies, and poor clinical outcome. Thus, we tackle GSDMB cytoplasmic overexpression as a new therapeutic target in HER2 breast cancers. Experimental Design: We have developed a new targeted nanomedicine based on hyaluronic acid–biocompatible nanocapsules, which allow the intracellular delivery of a specific anti-GSDMB antibody into HER2 breast cancer cells both in vitro and in vivo. Results: Using different models of HER2 breast cancer cells, we show that anti-GSDMB antibody loaded to nanocapsules has significant and specific effects on GSDMB-overexpressing cancer cells' behavior in ways such as (i) lowering the in vitro cell migration induced by GSDMB; (ii) enhancing the sensitivity to trastuzumab; (iii) reducing tumor growth by increasing apoptotic rate in orthotopic breast cancer xenografts; and (iv) diminishing lung metastasis in MDA-MB-231-HER2 cells in vivo. Moreover, at a mechanistic level, we have shown that AbGB increases GSDMB binding to sulfatides and consequently decreases migratory cell behavior and may upregulate the potential intrinsic procell death activity of GSDMB. Conclusions: Our findings portray the first evidence of the effectiveness and specificity of an antibody-based nanomedicine that targets an intracellular oncoprotein. We have proved that intracellular-delivered anti-GSDMB reduces diverse protumor GSDMB functions (migration, metastasis, and resistance to therapy) in an efficient and specific way, thus providing a new targeted therapeutic strategy in aggressive HER2 cancers with poor prognosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-2381

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 118

Metadata

Authors
Molina-Crespo, Á., Cadete, A., Sarrio, D., Gámez-Chiachio, M., Martinez, L., Chao, K., Olivera, A., Gonella, A., Díaz, E., Palacios, J., Dhal, P. K., Besev, M., Rodríguez-Serrano, M., García Bermejo, M. L., Triviño, J. C., Cano, A., García-Fuentes, M., Herzberg, O., Torres, D., Alonso, M. J., & Moreno-Bueno, G.
Venue
Clinical Cancer Research
Published
2019-08-01
Volume
25
Issue
15
Pages
4846-4858
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2943983202
Cited by
118
References
5
FWCI
3.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-2381
The paper
Molina-Crespo, Á., Cadete, A., Sarrio, D., Gámez-Chiachio, M., Martinez, L., Chao, K., Olivera, A., Gonella, A., Díaz, E., Palacios, J., Dhal, P. K., Besev, M., Rodríguez-Serrano, M., García Bermejo, M. L., Triviño, J. C., Cano, A., García-Fuentes, M., Herzberg, O., Torres, D., . . . Moreno-Bueno, G. (2019). Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-2381

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.